Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heberbiovac HB
- Development stage
- Phase 4
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Heberbiovac HB is a recombinant DNA vaccine produced by expressing the hepatitis B surface antigen (HBsAg) in the yeast *Saccharomyces cerevisiae*. Developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba, it is primarily indicated for the active immunization against hepatitis B virus (HBV) infection. The vaccine stimulates the immune system to produce specific neutralizing antibodies (anti-HBs) against the viral surface protein, providing long-term protection against liver failure, cirrhosis, and hepatocellular carcinoma caused by HBV. Since its approval in Cuba in 1992, it has been integrated into national newborn vaccination programs and is prequalified by the WHO/PAHO, with use extending to over 30 countries. It also serves as a platform for other multi-antigen formulations, such as pentavalent vaccines.
- Brand names
- Heberbiovac HBHeberbiovac-HB 20Heberbiovac-HB20Heberbiovac-HB-20
- Other names
- recombinant hepatitis B vaccineCuban recombinant hepatitis B vaccinerecombinant HBsAg vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Heberbiovac HB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heberbiovac HB.